stockrow
Saturday 7 November 2026
Export NGNE’s income statement to Excel — free account
Neurogene Inc.
NGNE Healthcare Biotechnology
Neurogene Inc.’s revenue for fiscal 2024 (year ended December 2024) was $925,000.00.
- EPS
- −45.7%
- Free cash flow
- −23.0%
- Total debt
- −66.7%
Quarter to June 2026, against a year earlier
25.29
0.36
−1.40%
Follow NGNE
Alert me
Neurogene Inc. (NGNE) P/E ratio
Neurogene Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2024 | 0.0× | — |
| Jun 2018 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NGNE Neurogene Inc. | n/m |
| FTH Faeth Therapeutics, Inc. compare | n/m |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR compare | n/m |
| ENTX Entera Bio Ltd. compare | n/m |
| OVID Ovid Therapeutics compare | n/m |
| CLYM Climb Bio, Inc. compare | n/m |
| PBYI Puma Biotechnology, Inc. compare | 15.3× |
| YDES YD Bio Limited compare | — |
| SLBT SL SCIENCE HLDG compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)